{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:06:28Z","timestamp":1788051988568,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402381"],"award-info":[{"award-number":["81402381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.cllc.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T21:22:43Z","timestamp":1530048163000},"page":"e831-e842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non\u2013small-cell Lung Cancer"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-0528","authenticated-orcid":false,"given":"Fengying","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.06.002_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib3","author":"Howlader"},{"key":"10.1016\/j.cllc.2018.06.002_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/ajco.12608","article-title":"China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)","volume":"13","author":"Shi","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib5","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.cllc.2018.06.002_bib6","first-page":"203","article-title":"Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies","volume":"24","author":"Pluda","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2018.06.002_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-6147(00)01676-X","article-title":"FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition","volume":"22","author":"Cross","year":"2001","journal-title":"Trends Pharmacol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.cllc.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.5-suppl_1-3","article-title":"VEGF receptor signaling in tumor angiogenesis","volume":"5","author":"McMahon","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2016.03.013","article-title":"Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment","volume":"96","author":"Epstein Shochet","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.002_bib11","first-page":"469","article-title":"Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis","volume":"39","author":"Shibuya","year":"2006","journal-title":"J\u00a0Biochem Mol Biol"},{"key":"10.1016\/j.cllc.2018.06.002_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.cllc.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in\u00a0vitro and in\u00a0vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cllc.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1200\/jco.2012.30.15_suppl.7548","article-title":"A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens","volume":"30","author":"Zhang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib17","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2147\/OTT.S113435","article-title":"Salvage treatment with apatinib for advanced non-small-cell lung cancer","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2018.06.002_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.12834","article-title":"Clinical response to apatinib monotherapy in advanced non-small cell lung cancer","volume":"14","author":"Xu","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib20","first-page":"761","article-title":"[Efficacy and survival analysis of apatinib in patients with advanced nonsquamous non-small cell lung cancer after failure of first-line treatment]","volume":"20","author":"Wang","year":"2017","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.cllc.2018.06.002_bib21","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.18632\/oncotarget.23612","article-title":"Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR","volume":"9","author":"Fang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2018.06.002_bib25","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/JTO.0b013e318220c93e","article-title":"Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer","volume":"6","author":"Tan","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A\u00a0retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.002_bib28","first-page":"115","article-title":"Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines","volume":"28","author":"Li","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cllc.2018.06.002_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2478\/v10039-011-0043-x","article-title":"Blocking the PI3K\/AKT and MEK\/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines","volume":"56","author":"Li","year":"2011","journal-title":"Adv Med Sci"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/JCO.2017.35.15_suppl.9004","volume":"35","author":"Bennouna","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.002_bib31","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","article-title":"Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters","volume":"70","author":"Mi","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2018.06.002_bib33","doi-asserted-by":"crossref","first-page":"e14069","DOI":"10.1200\/JCO.2017.35.15_suppl.e14069","article-title":"Combined treatment of apatinib with docetaxel in non-small-cell lung cancer mice and its material basis of pharmacokinetics","volume":"35","author":"Zhou","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041830161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:31Z","timestamp":1761505711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041830161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S152573041830161X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non\u2013small-cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}